EPR effect for cancer and inflammation

The field of nanomedicine, despite being conceptualized as far back as the 1980’s, is only now transitioning in a broad sense from academic research to drug development and commercialization. In oncology, unique structural features of many solid tumors including hyper-vasculature, defective vascular architecture, and impaired lymphatic drainage leading to the well characterized enhanced permeability and retention (EPR) effect are key factors in advancing this platform technology. However, the EPR effect has been measured mostly if not exclusively in implanted tumors with limited data on EPR in metastatic lesions in both mice and patients

    Related Conference of EPR effect for cancer and inflammation

    February 24-25, 2025

    2nd International Conference on Pharmacognosy

    Madrid, Spain
    February 27-28, 2025

    8th International on Pharmacy and Pharmaceutical Conference

    Prague, Czech Republic
    March 10-11, 2025

    35th Annual European Pharma Congress

    Rome, Italy
    April 14-15, 2025

    18th European Biosimilars Congress

    Paris, France
    April 24-25, 2025

    18th World Drug Delivery Summit

    London, UK
    May 05-06, 2025

    19th World Drug Delivery Summit

    Vancouver, Canada
    June 16-17, 2025

    3rd Global Online Summit on Nanoscience and Nanotechnology

    Zurich, Switzerland
    September 23-24, 2025

    10th International Conference on Future Pharma and Innovations

    Amsterdam, Netherlands
    November 27-28, 2025

    4th World Conference on Pharma Industry and Medical Devices

    Zurich, Switzerland
    November 27-28, 2025

    4th World Congress on Precision and Personalized Medicine

    Zurich, Switzerland

    EPR effect for cancer and inflammation Conference Speakers

      Recommended Sessions

      Related Journals

      Are you interested in